INR - PRWeb Press Release Account Feed http://www.rsspad.com/rss2a/51572.xml INR - Press Releases en xml@emediawire.com xml@emediawire.com 30 Repurposing of Enbrel for Alzheimer's Disease http://www.prweb.com/releases/etanercept/alzheimers/prweb1412984.htm At Cambridge Healthtech Institute's Third Annual Drug Repositioning Summit on Monday, October 6 in Boston, the audience is scheduled to hear, as a Keynote Presentation, the story of how an individual physician has charted an entirely new course for a therapeutic which is already one of the most successful of all time. The Keynote Presentation, entitled "Repurposing of Enbrel for Alzheimer's Disease" will be made by Edward Tobinick MD, Director of the Institute for Neurological Research, a private medical group, inc. in Los Angeles. Dr. Tobinick is the inventor and patent holder of the etanercept off-label indication for Alzheimer's Disease, as well as more than 200 different inventions involving new off-label uses of TNF blockers, such as etanercept, in neurology, opthalmology, and for a variety of additional innovative clinical indications. (PRWeb Oct 2, 2008)

Read the full story at http://www.prweb.com/releases/etanercept/alzheimers/prweb1412984.htm

]]> http://www.prweb.com/releases/etanercept/alzheimers/prweb1412984.htm World Alzheimer's Day 2008 Special Report: New Alzheimer Targets Take Center Stage http://www.prweb.com/releases/Alzheimers/etanercept/prweb1358314.htm World Alzheimer's Day 2008 Special Report: New innovative treatment approaches in Alzheimer's disease which involve mechanisms other than a direct attack on amyloid plaques have emerged as the leading candidates in the fight against Alzheimer's in 2008. These approaches were presented at ICAD 2008, the world's leading forum on dementia research. These new developments are discussed in the debut of AlzheimerVideoNews.com, a new website which takes a critical look at the most important news in Alzheimer's research. (PRWeb Sep 24, 2008)

Read the full story at http://www.prweb.com/releases/Alzheimers/etanercept/prweb1358314.htm

]]> http://www.prweb.com/releases/Alzheimers/etanercept/prweb1358314.htm New Drug May Help Combat Alzheimer's http://www.prweb.com/releases/2008/08/prweb1175274.htm Rapid improvement in verbal abilities, word finding, and aphasia in Alzheimer's disease and related forms of dementia following initiation of a new immune treatment is reported. These findings may be related to immune regulation of brain function, providing an exciting new area for Alzheimer research. (PRWeb Aug 6, 2008)

Read the full story at http://www.prweb.com/releases/2008/08/prweb1175274.htm

]]> http://www.prweb.com/releases/2008/08/prweb1175274.htm The Consumer Guide to Laser Hair Removal Answers Consumers Most Asked Laser Questions http://www.prweb.com/releases/2007/10/prweb562994.htm The "Consumer Guide to Laser Hair Removal" has been a leading online source for laser hair removal information for more than five years. (PRWeb Oct 23, 2007)

Read the full story at http://www.prweb.com/releases/2007/10/prweb562994.htm

]]> http://www.prweb.com/releases/2007/10/prweb562994.htm New Anti-TNF Approach for Alzheimer's Disease http://www.prweb.com/releases/2007/05/prweb524809.htm A radically new approach to Alzheimer's Disease treatment is detailed in a new U.S. patent which issued today. In U.S. patent 7214658, Edward Tobinick MD, Medical Director of the Institute for Neurological Research, a private medical group, inc. in Los Angeles, describes this novel approach which attacks excess TNF-alpha, a molecule which has been called the "master regulator" of the immune response. (PRWeb May 8, 2007)

Read the full story at http://www.prweb.com/releases/2007/05/prweb524809.htm

]]> http://www.prweb.com/releases/2007/05/prweb524809.htm New U.S. Patent 6,982,089 Issued - Describing a Novel Biotechnology Approach to Alzheimer's Disease http://www.prweb.com/releases/2006/02/prweb329301.htm New U.S. patent 6,982,089, describing perispinal administration of biological TNF-alpha modulators for certain neurological disorders, issued on January 3, 2006, awarded to Edward Tobinick, MD, Los Angeles, California. (PRWeb Feb 20, 2006)

Read the full story at http://www.prweb.com/releases/2006/02/prweb329301.htm

]]> http://www.prweb.com/releases/2006/02/prweb329301.htm Avian Influenza (" Bird Flu "): Study of Combination Therapy Utilizing Biologic TNF Inhibitors and Neuraminidase Inhibitors May be Warranted http://www.prweb.com/releases/2004/01/prweb101209.htm A potential new therapeutic approach utilizing biologic TNF-alpha inhibitors to attempt to reduce the morbidity and mortality associated with both SARS and avian influenza (H5N1 influenza) (" bird flu ") in humans is described in a newly published research letter. (PRWeb Jan 29, 2004)

Read the full story at http://www.prweb.com/releases/2004/01/prweb101209.htm

]]> http://www.prweb.com/releases/2004/01/prweb101209.htm Potential new SARS treatment approach is described http://www.prweb.com/releases/2003/10/prweb85131.htm Based on clinical and experimental evidence, a potential new medical approach to ameliorate the immune-based pulmonary damage, which is largely responsible for SARS mortality, is described. (PRWeb Oct 27, 2003)

Read the full story at http://www.prweb.com/releases/2003/10/prweb85131.htm

]]> http://www.prweb.com/releases/2003/10/prweb85131.htm U.S. patent 6,623,736 describing the use ofIL-1 inhibitors to treat retinal disorders issues http://www.prweb.com/releases/2003/09/prweb78647.htm Methods of use of specific recombinant DNA biotechnology drugs, which inhibit the action of the inflammatory cytokine IL-1, for the potential treatment of retinal disorders, including macular degeneration, diabetic retinopathy, and retinitis pigmentosa, are described in this newly issued U.S. patent. (PRWeb Sep 24, 2003)

Read the full story at http://www.prweb.com/releases/2003/09/prweb78647.htm

]]> http://www.prweb.com/releases/2003/09/prweb78647.htm Potential use of etanercept in cancer treatment is detailed in new medical report http://www.prweb.com/releases/2003/08/prweb76787.htm Pain due to cancer destruction of bone may potentially respond to anatomically targeted treatment utilizing etanercept, a biologic inhibitor of the cytokine TNF-alpha, as detailed in two new case reports. Initiation of randomized clinical trials is urgently needed. (PRWeb Aug 20, 2003)

Read the full story at http://www.prweb.com/releases/2003/08/prweb76787.htm

]]> http://www.prweb.com/releases/2003/08/prweb76787.htm Australian patent describing new methods of use for anti-TNF medications awarded to California physician http://www.prweb.com/releases/2003/08/prweb64839.htm Australian patent 758,523, entitled "TNF antagonists for the treatment of neurological disorders" has issued, awarded to Edward Tobinick, MD. Scientific support for the treatment methods described has now been reported, most recently from EULAR 2003, the leading European Rheumatology Congress. (PRWeb Aug 7, 2003)

Read the full story at http://www.prweb.com/releases/2003/08/prweb64839.htm

]]> http://www.prweb.com/releases/2003/08/prweb64839.htm Institute Research Associates, A Medical Group, Inc. Announces the Issuance of a New U.S. Patent Detailing Novel Clinical Methods of use for TNF-Alpha Antagonists http://www.prweb.com/releases/2003/04/prweb62190.htm New U.S. patent, covering novel methods of use for TNF-alpha antagonists, is awarded to Edward Tobinick, M.D., Medical Director. (PRWeb Apr 6, 2003)

Read the full story at http://www.prweb.com/releases/2003/04/prweb62190.htm

]]> http://www.prweb.com/releases/2003/04/prweb62190.htm